Novonesis completes MicroBioGen acquisition: Novonesis stock trades EUR 55.72
Published on 10/03/2026 at 11:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novonesis announced on October 1, 2026, that it had completed its acquisition of MicroBioGen after receiving all regulatory approvals, according to GlobeNewswire. Novonesis stock was quoted at EUR 55.72 by Lang & Schwarz at 11:25 a.m. CEST on October 3, 2026, unchanged from the close of EUR 55.72 on October 2, 2026.
Weekend trading
Lang & Schwarz quoted Novonesis at EUR 55.72 in weekend trading at 11:25 a.m. CEST on October 3, 2026. The bid was EUR 55.64 and the ask was EUR 55.80. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Novonesis stock.
Last Xetra trading day
The close at Lang & Schwarz was EUR 55.72 on October 2, 2026. The current weekend quote therefore matched that reference price.
MicroBioGen acquisition
Novonesis said MicroBioGen is an Australian biotechnology company with expertise in yeast strains for industrial applications and a track record in bioethanol. The transaction builds on Novonesis' investment in MicroBioGen in 2013 and its existing 23 percent ownership stake. Novonesis said the acquisition strengthens its yeast and research and development expertise and could support biosolutions across several industries. The company also said it would continue supporting MicroBioGen's existing partners. These details were reported in the Novonesis release distributed by GlobeNewswire.
Share buyback
In a separate September 14, 2026 announcement, Novonesis said it would initiate the first tranche of its EUR 1 billion multi-year share buyback program. The tranche covers purchases of B shares for an aggregate amount of up to EUR 75 million and was expected to end no later than December 17, 2026. The shares are intended to meet obligations from employee share-based incentive programs, according to GlobeNewswire.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
